Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...

LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine ...

Eli Lilly and Company and SiteOne Therapeutics, Inc., a private biotechnology company developing small molecule inhibitors of ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

In this week’s edition of InnovationRx, we look at how Hinge Health’s successful IPO may be a trendsetter, Indian billionaire ...

Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...